<DOC>
	<DOCNO>NCT02364453</DOCNO>
	<brief_summary>The purpose study determine effect antihistamine ( Clemastin ) migraine trigger pituitary adenylate cyclase activate peptide-38 ( PACAP38 ) well biochemical marker mast cell degranulation migraine patient . Also , investigate occurrence migraine migraine patient infusion PACAP38 low dosages previously investigate . As never do unknown low dose PACAP38 affect 1 ) incidence migraine attack , 2 ) accompanying symptom , 3 ) head pain characteristic , 4 ) debut duration migraine attack . Our three hypothesis : 1 . Pre-treatment Clemastin reduces PACAP38 sensitivity inhibits development migraine migraine patient . 2 . Clemastin inhibits increase plasma concentration TNF-alpha , histamine tryptase PACAP38-infusion . 3 . PACAP38 low dosage ( 4 , 6 8 pmol/kg/min ) induce migraine migraine patient .</brief_summary>
	<brief_title>The Effect Histamine H1 Receptor Antagonist , Clemastin , PACAP38 Induced Headache Migraine Patients</brief_title>
	<detailed_description>The purpose study determine effect antihistamine ( Clemastin ) migraine trigger pituitary adenylate cyclase activate peptide-38 ( PACAP38 ) well biochemical marker mast cell degranulation migraine patient . Also , investigate occurrence migraine migraine patient infusion PACAP38 low dosages previously investigate . As never do unknown low dose PACAP38 affect 1 ) incidence migraine attack , 2 ) accompanying symptom , 3 ) head pain characteristic , 4 ) debut duration migraine attack .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>migraine patient fulfil IHS criterion migraine without aura , age 1850 , 50100 kg , fertile woman must use safe prevention type primary headache migraine headache trial day later 48 hour trial day migraine three day trial day type cardiovascular disease clinical sign patient history type illness medical doctor charge trial deem relevant participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>